The satisfactory 2.7 years cash runway is overshadowed by increased cash burn rate of 19%. The firm's potential to raise funds for growth via new shares may entail dilution of existing ones. Close monitoring of Zentalis Pharmaceuticals' cash burn situation advised.
ゼンタリス・ファーマシューティカルズに関するコメント
Green
コラムToday's pre-market stock movers: MSFT, GOOG, BA, SPOT and more
• $エンフェーズ・エナジー(ENPH.US)$ +8.2% (earnings reports)
• $ゼンタリス・ファーマシューティカルズ(ZNTL.US)$ +7.6% (announces $25 mln equity investment from Pfizer (PFE); enters into development collaboration for ZN-c3)
• $テルニウム(TX.US)$ +6.1% (earnings reports)
• $ピュアサイクル・テクノロジーズ(PCT.US)$ +5% (SEC concludes investigation without further action)
• $アライアンス・リソース・パートナーズ(ARLP.US)$ +4.7% (increases dividend; provides prelim qtrly results)
• $Digital World Acquisition Corp(DWAC.US)$ +4.5% (cu...
コラムTop upgrades and downgrades on 4/6
• $バンク・オブ・カリフォルニア(BANC.US)$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $カレン・フロスト・バンカーズ(CFR.US)$: Raymond James Upgrades to Outperform from Market Perform
• $W・W・グレインジャー(GWW.US)$: Wolfe Research Upgrades to Outperform from Peerperform
• $インビテーション・ホームズ(INVH.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCBバンコープ(PCB.US)$: Raymond James Upgrades to Outperform from Market Perfor...
まだコメントはありません